Science Magazine· @ScienceMagazine · X·· 8 天前AI 评分25
AI 导读
一篇新的#ScienceReview重点介绍了肥胖管理药物(OMMs)的研发进展,包括GLP-1受体激动剂,以及这些药物相关的主要局限性,如胃肠道副作用、治疗反应差异、肌肉量流失和停药后体重反弹。 了解更多:https://scim.ag/4eDUQpN
正文
A new #ScienceReview highlights progress in the development of obesity management medications (OMMs), including GLP-1 receptor agonists, as well as key limitations associated with these medications, such as gastrointestinal side effects, variable treatment responses, loss of muscle mass, and weight regain after stopping treatment.
Learn more: https://scim.ag/4eDUQpN
来源:Science Magazine · x.com